Literature DB >> 12052197

5-HT(4) receptor antagonists: structure-affinity relationships and ligand-receptor interactions.

M L López-Rodriguez1, B Benhamú, M J Morcillo, M Murcia, A Viso, M Campillo, L Pardob.   

Abstract

Among serotonin receptors (5-HTRs), the 5-HT(4) subtype is of considerable interest because it is involved in (patho)physiological processes both in peripheral and central nervous systems. In addition to the clinical use of 5-HT(4R) agonists in the treatment of gastrointestinal motility disorders, the potential use of antagonists in the treatment of irritable bowel syndrome, arrhythmias and micturition disturbances are currently under investigation. This article will review the development of the most important classes of 5-HT(4R) antagonists with an emphasis on benzimidazole derivatives, their structure-affinity relationships, ligand-receptor interactions and pharmacological applications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052197     DOI: 10.2174/1568026023393769

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  3 in total

1.  1-Isopropyl-4-nitro-6-meth-oxy-1H-benzimidazole.

Authors:  Michael D Moore; Prashi Jain; Patrick T Flaherty; Peter L D Wildfong
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-06-25

2.  New insights into the human 5-HT4 receptor binding site: exploration of a hydrophobic pocket.

Authors:  Lucie Rivail; Mireille Giner; Monique Gastineau; Magali Berthouze; Jean-Louis Soulier; Rodolphe Fischmeister; Frank Lezoualc'h; Bernard Maigret; Sames Sicsic; Isabelle Berque-Bestel
Journal:  Br J Pharmacol       Date:  2004-09-06       Impact factor: 8.739

3.  Benzimidazole derivatives. 4. The recognition of the voluminous substituent attached to the basic amino group of 5-HT4 receptor antagonists.

Authors:  Maria L López-Rodríguez; Bellinda Benhamú; Marta Murcia; Elsa Alvaro; Mercedes Campillo; Leonardo Pardo
Journal:  J Comput Aided Mol Des       Date:  2003-08       Impact factor: 3.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.